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The arenavirus envelope glycoprotein (GPC) mediates viral entry through pH-induced membrane fusion in
the endosome. This crucial process in the viral life cycle can be specifically inhibited in the New World
arenaviruses by the small-molecule compound ST-294. Here, we show that ST-294 interferes with GPC-
mediated membrane fusion by targeting the interaction of the G2 fusion subunit with the stable signal peptide
(SSP). We demonstrate that amino acid substitutions at lysine-33 of the Junín virus SSP confer resistance to
ST-294 and engender de novo sensitivity to ST-161, a chemically distinct inhibitor of the Old World Lassa fever
virus. These compounds, as well as a broadly active inhibitor, ST-193, likely share a molecular target at the
SSP-G2 interface. We also show that both ST-294 and ST-193 inhibit pH-induced dissociation of the G1
receptor-binding subunit from GPC, a process concomitant with fusion activation. Interestingly, the inhibitory
activity of these molecules can in some cases be overcome by further lowering the pH used for activation. Our
results suggest that these small molecules act to stabilize the prefusion GPC complex against acidic pH. The
pH-sensitive interaction between SSP and G2 in GPC represents a robust molecular target for the development
of antiviral compounds for the treatment of arenavirus hemorrhagic fevers.
Arenaviridae comprise a large family of enveloped, negative-
strand RNA viruses whose species have coevolved and diver-
sified with their respective rodent hosts (10, 45). Many arena-
virus species are nonpathogenic to humans, but several can be
transmitted to cause severe acute hemorrhagic fevers. In the
so-called Old World group of arenaviruses, Lassa fever virus
(LASV) is responsible for up to 300,000 infections annually in
western Africa (36). Although arenavirus disease is less prev-
alent in the Americas (40), four distinct species of New World
arenaviruses are recognized to cause fatal hemorrhagic fevers:
the Junín (JUNV), Machupo, Guanarito, and Sabiá viruses.
New species of disease-associated arenaviruses continue to be
identified (8, 13). Without effective treatment or immuniza-
tion, the hemorrhagic fever arenaviruses remain an urgent
public health and biodefense concern.
Arenavirus entry into its host cell is promoted by the virus
envelope glycoprotein (GPC) and provides a potential target
for therapeutic intervention. The G1 subunit of the GPC com-
plex initiates infection by binding to a cell surface receptor.
The pathogenic New World arenaviruses utilize transferrin
receptor 1 for entry (41, 42), whereas nonpathogenic New
World viruses and Old World viruses bind -dystroglycan or an
unknown receptor (6, 20, 49). Upon receptor binding, the
virion is endocytosed (4), and fusion of the viral and cellular
membranes is subsequently activated by acidic pH in the ma-
turing endosome (7, 14, 15). The mechanics of membrane
fusion are promoted by the transmembrane fusion subunit, G2.
As is characteristic of other class I virus fusion proteins (16, 17,
26, 29, 48), activation of the prefusion GPC complex is fol-
lowed by a structural reorganization of the G2 ectodomain that
leads to formation of a highly stable six-helix bundle and to
membrane fusion (19, 24, 53).
GPC is unusual among class I envelope glycoproteins in that
the mature complex retains its cleaved signal peptide as an
essential subunit (5, 18, 58) (Fig. 1). This stable signal peptide
(SSP) contains 58 amino acids and spans the membrane twice,
with both N and C termini in the cytosol (1). SSP is likely
retained in the mature GPC complex by formation of an in-
tersubunit zinc-finger structure with the cytoplasmic domain of
G2 (55). Interestingly, amino acid substitutions at a lysine in
the short ectodomain loop of SSP (K33) have been shown to
modulate the pH at which membrane fusion is activated (57).
Because the charge at K33 is itself not altered by acidic pH, we
reasoned that the lysine side chain might respond to a titrat-
able pocket in the ectodomain of G2. Thus, SSP and G2 may
interact to mediate the pH-induced transition from the meta-
stable prefusion GPC complex to the activated fusion-compe-
tent form, whereupon the structural reorganization in G2 is
actuated to drive membrane fusion. In this report, we demon-
strate that the recently reported small-molecule inhibitor of
arenavirus entry, ST-294 (3), prevents membrane fusion by
targeting the SSP-G2 interface and stabilizing the prefusion
state of GPC against acidic pH.
MATERIALS AND METHODS
Molecular and chemical reagents and monoclonal antibodies (MAbs). GPC
from the pathogenic JUNV strain MC2 (25) was expressed in Vero cells by
transfection using a pcDNA3.1-based plasmid carrying the complete GPC open
reading frame or by cotransfection using plasmids encoding CD4sp-GPC (in
which SSP is replaced by the conventional signal peptide of CD4) and SSP-term
(in which a stop codon is introduced following the C-terminal SSP amino acid
T58) (57). These two components associate in trans and reconstitute the native
GPC complex (18). The GPC open reading frame of LASV-Josiah (33) and that
of the vesicular stomatitis virus (VSV) G glycoprotein (kindly provided by John
K. Rose, Yale University) were also expressed in pcDNA3.1 plasmids. Transient
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expression utilized a recombinant vaccinia virus expressing T7 RNA polymerase
(vTF7-3) (23). Mutations in GPC were introduced by QuikChange mutagenesis
(Stratagene), and all constructs were verified by DNA sequencing.
The small-molecule fusion inhibitors ST-294, ST-336 (3), ST-193 (33), and
ST-161 (unpublished data) were dissolved in dimethyl sulfoxide. Chemical struc-
tures are shown in Fig. 2. The murine MAb BF11 (46), directed to G1, was
contributed by Tom Ksiasek and Tony Sanchez (Special Pathogens Branch,
CDC, Atlanta, GA) and obtained through the NIH Biodefense and Emerging
Infections Research Resources Repository.
Cell-cell fusion assay. A vaccinia virus-based -galactosidase fusion reporter
assay (39) was used to characterize the ability of GPC to mediate pH-dependent
cell-cell fusion (57, 58). Briefly, Vero cells infected by vTF-7 and expressing GPC
were maintained in 10 M of cytosine arabinoside (araC) to limit vaccinia virus
replication. Target cells for syncytium formation were infected with a recombi-
nant vaccinia virus bearing the -galactosidase gene under the control of a T7
promoter (vCB21R-lacZ) (39) and seeded into 96-well microculture dishes
(40,000 cells/well) in the presence of 100 g rifampin/ml to minimize vaccinia
virus assembly and cytopathic effect (28). Prior to use in the cell-cell fusion assay,
target cells (40,000 cells/well) were added to the microcultures, allowed to settle
for 30 min, and subjected to a brief low-speed centrifugation (25  g) to ensure
cell-cell contact. These cocultures were continued for 3 h in medium containing
araC and rifampin. Membrane fusion was initiated by incubation in drug-con-
taining medium that had been adjusted to low pH by using HEPES and PIPES
[piperazine-N,N-bis(2-ethyanesulfonic acid)] buffers. After 10 to 30 min at 37°C,
the cells were restored to the neutral drug-containing medium and cultured for
5 h to allow for expression of the -galactosidase fusion reporter gene, which was
then quantitated using the chemiluminescent GalactoLite Plus substrate and a
Tropix TR717 microplate luminometer. The wide dynamic range of the assay
permits robust measurement of 1% of wild-type activity. This low level is
routinely 10-fold greater than that measured using nonfusogenic GPC molecules
(e.g., CD4spGPC in the absence of SSP or a cleavage-defective mutant) (58) or
upon treatment of cells expressing wild-type GPC at neutral pH.
For studies of fusion inhibition, cells were incubated with serial dilutions of the
compounds developed by SIGA Technologies throughout the initial 3.5-h period
of coculture. In these studies, 4 to 6 replicate wells were used for each determi-
nation, and control cocultures were treated with the dimethyl sulfoxide solvent
(which did not affect the assay at final concentrations of 0.25%). In preliminary
studies, inhibitor was added prior to, during, or after the pH pulse to show that
pretreatment was both necessary and sufficient for inhibition (Fig. 3B).
G1 shedding. pH-induced shedding of the G1 subunit from metabolically
labeled cells was detected by immunoprecipitation (57, 58) from the low-pH
culture supernatant. Vero cells expressing GPC as described above were sus-
pended and pulsed at the indicated pH for 10 min at 37°C. Cells were also treated
in medium adjusted to pH 2.5 in an effort to normalize G1 shedding relative to
the total amount of G1 eluted under highly stringent conditions. In studies of
fusion inhibition, the cell suspension was pretreated for 30 min with the SIGA
compounds. The low-pH medium was recovered and neutralized prior to cen-
trifugation to remove cell debris and shed membranes. G1 was recovered from
this supernatant by immunoprecipitation using MAb BF11 (46) and protein A
Sepharose (Sigma) in buffers containing 1% Triton X-100. The glycoprotein was
FIG. 1. Arenavirus GPC complex. A representation of the JUNV GPC open reading frame is shown at the top. Amino acids are numbered from
the initiating methionine, and the SSP, G1, and G2 subunits are indicated. Membrane-spanning regions in SSP (h1 and h2) (1) and in G2 (TM)
are shaded dark gray, and the N- and C-terminal heptad-repeat regions in G2 (53) are in light gray. Long tick marks and the amino acids noted
above GPC represent ST-294 resistance mutations described in the text; short tick marks show other mutations examined. Below the schematic,
the amino acid sequences of SSP and the membrane-proximal region of G2 in JUNV, TCRV, and LASV are detailed (GenBank accession numbers
D10072, M20304 and J04324, respectively). The ST-294 resistance mutations in JUNV are indicated by brackets. At the right of the figure, we
illustrate our current model of the subunit organization in the tripartite GPC complex. Thickened sections of lines represent membrane-spanning
domains in SSP and G2 and the heptad-repeat regions in G2. The cytosolic N terminus of SSP is myristoylated (thin line) (58), and an intersubunit
zinc finger (circle) is thought to link the C terminus of SSP with the cytoplasmic domain of G2 (55). Mutations at K33 in the ectodomain of SSP
have previously been shown to modulate the pH of membrane fusion (57). The drawing is not to scale.
FIG. 2. SIGA fusion inhibitors. The New World arenavirus inhib-
itor ST-294 was developed from the initial hit compound ST-336 (3).
ST-161 (unpublished data) and ST-193 (33) were derived from sepa-
rate hit compounds identified by high-throughput screening using the
Old World LASV GPC.
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subsequently deglycosylated by using peptide N-glycosidase F (New England
Biolabs) (57) and resolved by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) under reducing conditions (NuPAGE 4–12% Bis-Tris
gel; Invitrogen). G1 shedding was quantitated in phosphostimulated lumines-
cence units by using a Fuji FLA-3000G imager and ImageGauge software.
RESULTS
ST-294 targets the prefusion form of GPC to inhibit cell-cell
fusion. ST-294 was developed by SIGA Technologies through
optimization of ST-336 (Fig. 2), a molecule first identified by
high-throughput screening for inhibition of cell culture infec-
tion with the nonpathogenic New World arenavirus Tacaribe
(TCRV) (3). This class of compounds inhibits in vitro infection
by the related New World arenaviruses JUNV, Machupo virus,
and Guanarito virus at submicromolar concentrations yet is
minimally active against the Old World LASV. Studies dem-
onstrated that these inhibitors bind to intact virions and act
prior to infection. TCRV isolates selected for in vitro resis-
tance to ST-336 had several mutations in G2 and none in G1
(3). Together, these data suggested that ST-294 acts upon the
virion GPC complex prior to the initial stages of cell infection.
To determine whether ST-294 directly inhibits the mem-
brane fusion activity of GPC, we investigated its ability to
inhibit syncytium formation among cells expressing a molecu-
larly cloned JUNV GPC (53). In this assay, Vero cells are
briefly pulsed with medium adjusted to pH 5.0 and cell-cell
fusion is assessed using a -galactosidase reporter gene (39).
As illustrated in the left panel of Fig. 3, we found that the
membrane fusion activity of JUNV GPC was sensitive to ST-
294, whereas pH-dependent cell-cell fusion by the unrelated G
protein of VSV was unaffected. In these studies, cell-cell fusion
was reduced to 50% at 4 M ST-294, whereas previous work
had determined a 50% inhibitory concentration (IC50) of 0.3
M for JUNV plaque reduction (3). The numerical difference
in the inhibitory concentrations likely reflects differences in-
herent in the two assays. Thus, ST-294 prevents arenavirus
entry by specifically inhibiting the membrane fusion activity
of GPC.
Studies had previously demonstrated that prior exposure of
virions to ST-336 was sufficient to block subsequent infection
of untreated cells (3). In order to determine the timing re-
quirements for inhibition of cell-cell fusion, GPC-expressing
cells were treated with 10 M ST-294 prior to the pH pulse,
during the pH pulse, or upon return to neutrality (Fig. 3, right
panel). Inhibition was observed only when ST-294 was in-
cluded prior to pulsing with pH 5.0. Pretreatment with 10 M
ST-294 reduced cell-cell fusion by 75%, and no additional
inhibition was seen if treatment was continued throughout.
Further inhibition could be detected upon pretreatment with
50 M ST-294. These findings support the conclusion that
these compounds act prior to infection (3) and demonstrate
clearly that ST-294 targets a prefusion form of the GPC com-
plex.
Mutations in G2 and SSP confer resistance to ST-294. ST-
336-resistant TCRV isolates encode mutations in the mem-
brane-proximal ectodomain and transmembrane domain of G2
(3). To determine whether the amino acid changes noted were
responsible for viral resistance, we introduced the individual
mutations (T416N, I418T, S433I, and F436I) into the homol-
ogous positions in JUNV GPC (T418N, L420T, A435I, and
F438I). The GPC mutants were expressed, proteolytically ma-
tured, and transported to the surface of the cell similarly to the
wild type (not shown) (53), and all were able to promote
cell-cell fusion, albeit to differing degrees. The relative fusion
competence levels of the mutants are indicated on the left
panel of Fig. 4A. All four mutants were highly resistant to 10
M ST-294 (Fig. 4A, right panel). Thus, each of the mutations
identified in the membrane-proximal and transmembrane do-
mains of G2 from ST-336-resistant TCRV isolates (3) also
rendered JUNV GPC resistant to ST-294.
Alanine-scanning mutagenesis was used to identify addi-
tional amino acid determinants of ST-294 resistance in the
membrane-proximal ectodomain of G2. We focused on the
large number of charged residues in this region (Fig. 1), some
of which may be positioned to interact with the critical K33
side chain in the ectodomain loop of SSP (57; unpublished
data). We also included an existing collection of mutations
spanning the N- and C-terminal heptad-repeat regions of the
G2 ectodomain (53). As in other class I fusion proteins, the N-
and C-terminal heptad repeats in the prefusion GPC complex
are sequestered in an unknown conformation and refold to
form the six-helix bundle structure during membrane fusion.
Of over 30 new and existing G2 mutants examined, 22 were
able to mediate cell-cell fusion at levels of 10% that of the
wild-type GPC (Fig. 4B, left panel). Three additional determi-
nants of ST-294 resistance were identified among these: I347A,
D400A, and F427A (Fig. 4B, right panel). I347 lies in the
N-terminal heptad repeat of G2, at an interhelical a-position in
the postfusion six-helix bundle, and the alanine mutation re-
duces membrane fusion to 40% of wild-type levels (53).
D400 is located in the C-terminal heptad repeat (53) at a
position expected to reside on the outer surface of the six-helix
bundle. D400A reduces cell-cell fusion to 75% of the wild
type. F427 is located near the ectodomain face of the predicted
FIG. 3. ST-294 inhibits JUNV GPC-mediated membrane fusion.
pH-dependent cell-cell fusion was initiated by a pulse of medium
adjusted to pH 5.0, detected using a recombinant vaccinia virus-based
-galactosidase-reporter assay, and quantified by chemiluminescence.
(A) Vero cells expressing JUNV GPC (filled circles) or VSV G protein
(open squares) were incubated with the indicated concentrations of
ST-294, washed, and then pulsed for 20 min with medium at pH 5.0.
The percentage of fusion relative to that of the control in the absence
of ST-294 is indicated. Error bars representing 	1 standard deviation
are calculated for all points and in some cases may not be visible on the
scale of the graph. (B) Cells expressing JUNV GPC were incubated
with ST-294 prior to (pre), during (pulse) or after (post) the pH pulse
(the numbers 10 or 50 represent the M concentration of ST-294).
Cell-cell fusion is reported as relative light units (RLUs) in the assay.
Pretreatment with ST-294 was necessary and sufficient for inhibition.
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transmembrane domain, between the L420T and A435I muta-
tions identified in ST-336-resistant TCRV, and F427A is com-
parable to the wild-type GPC in its membrane-fusion activity.
Although the seven resistance mutations span much of the G2
ectodomain, the three-dimensional relationship between these
residues in the prefusion GPC complex is unknown.
Six of the ST-294 resistance mutations (D400A, T418N,
L420T, F427A, A435I, and F438I), however, lie close in se-
quence to the nominal ectodomain face of the membrane,
where they may be positioned to interact with SSP (57). We
therefore extended our analysis of ST-294 resistance to include
residues in SSP (1, 56). For the 15 fusion-competent mutants
examined, only mutations at N37 and K33 in the ectodomain
loop of SSP were able to render GPC resistant to ST-294 (Fig.
4C). The K33R and K33H mutations, which have been shown
to reduce the pH threshold for membrane fusion (57), both
generated resistance to ST-294 (as did K33Q and K33E [not
shown]). Amino acid changes in the second membrane-span-
ning region of SSP (positions 41 through 54) did not signifi-
cantly affect membrane fusion activity (1) or sensitivity to ST-
294. Mutations in the two cytosolic regions of SSP—G2A (58),
E17A and R55A (57), and T58R (54)—did not appreciably
alter sensitivity. Thus, the ectodomain loop of SSP that is
critical in modulating the pH of fusion activation is also an
important determinant of inhibition by ST-294. The K40 resi-
due at the nominal C terminus of the ectodomain loop (57)
appears to not participate in determining sensitivity.
The K33H mutation confers sensitivity to Old World-spe-
cific inhibitors. SIGA Technologies has independently identi-
fied two distinct chemical classes of Old World arenavirus
fusion inhibitors (Fig. 2) through high-throughput screening
for molecules that prevent cell entry by pseudotyped retrovi-
ruses bearing the LASV GPC (33). We characterized the in-
hibitory activity of these new compounds, ST-161 and ST-193,
by using JUNV and LASV GPCs in cell-cell fusion assays.
ST-161 was found to be specific to LASV GPC and did not
inhibit cell-cell fusion by JUNV GPC (Fig. 5, left panel), while
the broadly active ST-193 molecule (33) was shown to inhibit
cell-cell fusion by both LASV and JUNV GPCs (Fig. 5, right
panel).
In order to probe the molecular basis for the inhibitory
activities of ST-161 and ST-193, we first investigated whether
these new inhibitors shared determinants of resistance with
ST-294. Of the four resistance mutations identified in TCRV,
we focused on L420T because of its good fusion activity and its
localization in the G2 ectodomain. The L420T mutant of
JUNV GPC remained insensitive to the Old World-specific
FIG. 4. Genetic analysis of ST-294 resistance. JUNV GPC was
expressed by cotransfection of plasmids encoding SSP (SSP-term) and
CD4sp-GPC (in which SSP is replaced by the conventional signal
peptide of human CD4) as previously described (57). Using trans-
complementation, we obviate concerns that mutations in SSP may
affect signal-peptidase cleavage. The G2 and SSP mutants listed on the
left were coexpressed with their respective wild-type partners. pH-
dependent membrane fusion was determined in the absence of ST-294
(gray bars) or upon pretreatment with 10 M ST-294 (black bars). The
left panel (% fusion) reports the percentage of fusion by the mutant
GPC relative to that by GPC comprising wild-type SSP and CD4sp-
GPC. The right panel (% resistance) reflects the extent of membrane
fusion in the presence of 10 M ST-294, relative to that of the un-
treated GPC. (A) Mutations in G2 originally identified in ST-336-
resistant TCRV isolates. The T418N mutation was surprisingly severe
in the JUNV background. (B and C) New and existing mutants in G2
and SSP, respectively. All points are representative of results for two or
more independent experiments.
FIG. 5. JUNV and LASV GPC sensitivities to ST-161 and ST-193.
Cells expressing trans-complemented wild-type JUNV GPC (filled cir-
cles), L420T JUNV GPC (filled squares), K33H JUNV GPC (filled
upright triangles), K33R JUNV GPC (filled inverted triangles), or
wild-type LASV GPC (open circles) were treated with the indicated
concentrations of ST-161 or ST-193 prior to pulsing with medium at
pH 5.0. The percentage of fusion relative to that of the inhibitor-
untreated control is indicated. Error bars represent 	1 standard de-
viation.
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inhibitor ST-161 but was now resistant to the broadly active
molecule ST-193 (Fig. 5, left panel). We also examined the
effect of ST-294 resistance mutations at K33. Remarkably, we
found that the K33H mutant JUNV GPC now exhibited de
novo sensitivity to the LASV-specific inhibitor ST-161 (Fig. 5,
left panel). Both K33H and K33R mutations also enhanced
sensitivity to ST-193 (Fig. 5, right panel).
Together, these results suggest that the three independently
identified chemical classes of arenavirus fusion inhibitors share
a common molecular target involving both SSP and G2. Sen-
sitivity among the different classes of inhibitors may be deter-
mined in part by SSP. However, because K33 is uniformly con-
served among naturally occurring arenaviruses (57), species
specificity is also determined by the amino acid diversity in G2.
Inhibitors prevent pH-induced G1 shedding from the GPC
complex. We have previously shown that amino acid substitu-
tions at K33 that decrease positive polarity (K33R, K33H,
K33Q, and K33E) systematically depress the pH needed for
activation of cell-cell fusion (57). Substitution of a nonpolar
alanine side chain at this position abolishes all evidence of
membrane fusion. In these studies, we also noted that K33A
mutant GPC retains much of its G1 subunit during biosynthe-
sis, as opposed to wild-type GPC in which the loss of G1 from
the complex is readily discerned (57). This observation sug-
gested that the K33A mutation may limit spontaneous disso-
ciation of the G1 subunit by stabilizing the GPC complex and
thereby prevent membrane fusion. Stabilization of the prefu-
sion GPC complex might likewise represent a possible mech-
anism of action of the SIGA inhibitors.
To investigate this notion, we made use of the observation in
class I envelope glycoproteins that the receptor-binding sub-
unit can be shed in response to the activation of membrane
fusion (32, 38). Partial dissociation of the receptor-binding
subunit is considered an early event in the conformational
cascade to membrane fusion in all class I proteins (16, 17, 26,
29, 48). In the absence of a covalent linkage between the
subunits, the receptor-binding subunit can be physically shed
from the complex concomitant with activation. Although the
functional relationship between shedding and membrane fu-
sion is uncertain (22, 37, 51), the degree of dissociation can
serve as a useful marker for both the stability of the prefusion
complex and its activation toward fusion (21, 32, 47, 52).
To determine whether G1 shedding is related to pH-induced
activation of GPC, we quantitated the amount of metabolically
labeled G1 shed from the cell surface during a 10-min incuba-
tion in low-pH media. Soluble G1 was collected by immuno-
precipitation from the neutralized medium, deglycosylated,
and resolved by SDS-PAGE. As illustrated in Fig. 6A, shed-
ding by the wild-type GPC complex was first evident at pH 5.0,
coincident with optimal membrane fusion. Unlike fusion, how-
ever, shedding continued to increase as pH was lowered to pH
4.0. No additional G1 was released upon treatment of the cells
at pH 2.5 (Fig. 6A), conditions likely to dissociate all mature
G1 from the cell surface. In contrast to wild-type GPC, no G1
was shed from the K33A mutant at pH 5.0 or 4.0, despite
ample amounts of G1 present on the cell surface (pH 2.5)
(Fig. 6A).
Taken together, these results suggest that G1 shedding from
the GPC complex is closely correlated with pH-induced acti-
vation of membrane fusion. Although the functional signifi-
cance of G1 shedding within the conformational cascade is
unclear, it is likely either a necessary or collateral consequence
of the pathway taken by GPC to membrane fusion. At least
partial dissociation early in the process would be required to
permit exposure of the sequestered G2 fusion subunit, inser-
tion of the G2 fusion peptide into the host-cell membrane, and
formation of the six-helix bundle structure (16, 17, 26, 29, 48).
The lack of G1 shedding by the K33A mutant at pH 5.0 is
consistent with its inability to mediate membrane fusion and
supports the notion that this mutation stabilizes the prefusion
GPC complex.
Shedding by the wild-type GPC at pH 5.0 was also reduced
by pretreatment with either 50 M ST-294 or 25 M ST-193
(Fig. 6B). Each compound reduced shedding by 20-fold, con-
sistent with the complete inhibition of membrane fusion (Fig.
3 and 5). By contrast, ST-161 is a very poor inhibitor of JUNV
membrane fusion activity (20% inhibition at 25 M [Fig. 5]).
Accordingly, pretreatment of JUNV GPC with 50 M ST-161
reduced G1 shedding minimally, to 50% of the untreated level
(Fig. 6B). These findings extend the correlation between G1
shedding and membrane fusion activity and suggest that the
SIGA fusion inhibitors act to stabilize the prefusion GPC com-
plex against low pH.
Fusion inhibition can be overcome by reduced pH. Stabili-
zation of the prefusion GPC complex can be accomplished by
mutation at K33 or by inhibitor binding. Substitutions at K33
lower the pH at which membrane fusion is activated (57), and
we wanted to determine whether inhibition by these small
molecules might be functionally linked to this pH-responsive
mechanism in GPC. If the metastable prefusion state of GPC
were stabilized by inhibitor binding in opposition to pH-in-
FIG. 6. Inhibition of pH-dependent G1 shedding by ST-294 and
ST-193. (A) G1 shed into the low-pH medium from metabolically
labeled cultures expressing wild-type (filled circles) or K33A (open
circles) GPC was collected by immunoprecipitation and deglycosylated
using peptide N-glycosidase F (New England Biolabs) (57). The G1
polypeptide was resolved by SDS-PAGE (image below graph) and
quantitated (graph) using ImageGauge software (Fuji). G1 radioactiv-
ity is expressed in phosphostimulated luminescence units. No mem-
brane-associated G1-G2 precursor was detected in the culture super-
natant (not shown). The source of a faster-migrating G1 species
released at pH 2.5 is unknown. (B) Cells expressing wild-type GPC were
incubated in medium containing 50 M of ST-294 and ST-161 or 25 M
ST-193 for 30 min. G1 shedding at pH 5.0 was determined by immuno-
precipitation (image below histogram), and is expressed as the fraction of
total amount of G1 eluted from the cell surface at pH 2.5. The data
displayed are representative of results obtained from three independent
experiments.
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duced destabilization, we reasoned that increased H concen-
tration might in some cases shift the balance between these
equilibria and overcome inhibition. This effect would manifest
as an increase in cell-cell fusion as pH is reduced in the pres-
ence of the inhibitor.
To test this hypothesis, we sought a relatively weak inhibitor
to establish experimental conditions under which the low bind-
ing affinity of the inhibitor might be more readily overcome by
an increase in H concentration. ST-193 had originally been
identified as an inhibitor of LASV GPC and was subsequently
found to be active against New World arenaviruses (33). Al-
though this molecule shows nanomolar potency against both
Old World and New World GPC in pseudotyped virions (33),
the IC50 against JUNV GPC in the cell-cell fusion assay is
markedly poorer than that with LASV GPC (0.9 M versus


50 nM, respectively) (Fig. 5, right panel). This may, in part,
reflect differences between the two assays. Based on this ob-
servation, however, we chose to determine whether inhibition
of cell-cell fusion by 25 M ST-193, which is effective at pH 5.0,
can be overcome at lower pH.
Indeed, whereas cell-cell fusion at pH 5.0 was inhibited by
90% using ST-193, membrane fusion was restored at pH 4.5
(Fig. 7A). The maximal extent of fusion in the presence of
ST-193 occurred at pH 4.5 and was only slightly reduced rel-
ative to that in the absence of inhibitor (at pH 5.0). When the
pH was lowered to 4.0, fusion by both treated and untreated
GPCs was markedly reduced, possibly due to inactivation of
the complex by excess protonation. We observed the same
depression in the pH of fusion by the K33H mutant of GPC
using ST-161. In the absence of inhibitor, the K33H mutation
itself reduces the pH threshold for membrane fusion such that
fusion is now maximal at pH 4.5 (Fig. 7B). In the presence of
50 M ST-161, the optimal pH was further reduced to 4.0.
The maximum extent of fusion with ST-161 (at pH 4.0) was
comparable to that in the absence of inhibitor (at pH 4.5). In
contrast to the case for wild-type GPC, the downward shift in
pH in the K33H mutant appeared to protect against inactiva-
tion at pH 4.0. Together, our findings that inhibition by ST-193
in wild-type GPC and inhibition by ST-161 in the K33H mutant
can be overcome experimentally by reduced pH are consistent
with a model of the prefusion GPC complex in which the
stabilizing effects of inhibitor binding and the destabilizing
effects of protonation are opposing and additive.
In contrast to ST-193, inhibition of JUNV GPC by ST-294
remained intact throughout the useable pH range (Fig. 7C). It
is possible that still-lower pH levels would be needed to coun-
teract the activity of ST-294, but these extreme cell culture
conditions were not examined. The basis for the difference in
the behaviors of ST-193 and ST-294 is not readily apparent
from their respective IC50 values, which are comparable (0.9
and 4 M). It is possible that overt inhibition involves both the
binding affinity of the compound and its inherent ability to
interfere in the activation process. Compounds that differ in
these components of inhibition may respond differently to pH.
These factors may have been differentially selected for during
screening and lead optimization. It is worth noting that ST-294
was identified through its inhibition of New World virus rep-
lication (3), whereas ST-193 and ST-161 were developed as
inhibitors of Old World GPC (33). Furthermore, the pH re-
quirement for viral entry in the endosome is itself undefined,
and thus, in vitro measures of inhibitor potency at pH 5.0 may
differ from those determined by virus infection.
The observed pH dependence in inhibitor potency raises the
possibility that resistance in the D400A mutant GPC (Fig. 4)
might also reflect a change in its intrinsic sensitivity to acidic
pH. As shown in Fig. 7D, the effect of the D400A mutation on
the pH of membrane fusion, if any, was quite small compared
to that of K33H. The slight increase in both fusion activity at
pH 5.5 and lability at pH 4.5 (relative to those of the wild type)
is clearly not correlated with ST-294 resistance in the D400A
mutant, as a similar pattern is observed in ST-294-sensitive
E410A and D424A mutants. Although E405A and K417A
GPCs exhibit the opposite trend in pH sensitivity, we should
emphasize that we cannot determine at present whether these
charged residues are involved in the activation of membrane
fusion.
DISCUSSION
Membrane fusion must be appropriately controlled to en-
able productive virus entry. The generally accepted model for
activation and progression to membrane fusion by class I viral
fusion proteins has been developed over several decades of
FIG. 7. Inhibition of JUNV GPC is sensitive to pH. Cells express-
ing wild-type JUNV GPC (A and C) or K33H GPC (B) by trans-
complementation were treated with 25 M ST-193 (panel A, open
squares), 50 M ST-161 (panel B, open triangles), 50 M ST-294
(panel C, open circles), or left untreated (all filled shapes). Cultures
were pulsed for 10 min with medium at the indicated pH, and the
extent of cell-cell fusion was determined (as RLUs). Error bars rep-
resent 	1 standard deviation. In panel D, we plot the pH sensitivities
of wild-type GPC (filled circles) and the ST-294-resistant D400A mu-
tant (filled squares). Sensitive mutants shown (open grey symbols) are:
E405A (circles), E410A (upright triangles), K417A (inverted trian-
gles), and D424A (diamonds). Fusion activity (in RLUs) is normalized
to that at pH 5.0 to remove differences in intrinsic activity among the
mutants. Although the results are representative of results for at least
three independent partial and complete experiments, the respective
GPCs are not statistically distinguishable in these studies. Error bars
have been omitted for clarity.
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now-classic research (reviewed in references 16, 17, 26, 29, and
48). The class I envelope glycoproteins are assembled as stable
but inert precursors that require proteolytic cleavage for fusion
activity. The fusion-competent envelope glycoprotein complex
is thought to exist in a metastable state, established on proteo-
lytic maturation and maintained by a balance of stabilizing and
destabilizing forces within the protein. For viruses such as
human immunodeficiency virus type 1 that enter through the
plasma membrane, the membrane fusion activity is subse-
quently triggered by binding to cell surface receptor(s) at neu-
tral pHs. Other viruses, including the arenaviruses and ortho-
myxoviruses, are endocytosed and exposed to acidic pH in
order to activate the fusion process. Upon activation, all class
I envelope glycoproteins undergo a structural reorganization
that follows a thermodynamically determined path toward for-
mation of the stable six-helix bundle and fusion of the virus and
cell membranes. Our results suggest that the SIGA inhibitors
prevent membrane fusion by stabilizing the prefusion GPC
complex against activation at low pH.
The molecular basis for pH-induced activation of envelope
glycoprotein-mediated membrane fusion is largely undefined.
Despite detailed structural knowledge of membrane fusion in
the best-studied pH-dependent envelope glycoprotein, influ-
enza virus hemagglutinin (HA), key elements of the activation
process remain to be completely elucidated (9, 43, 50). Studies
of tert-butyl hydroquinone HA fusion inhibitors have demon-
strated the metastable nature of the prefusion HA complex
and the ability of small molecules to stabilize against acidic
pHs (2, 27). In accordance with this mechanism of action,
tert-butyl hydroquinone-resistant mutants were found to dis-
play an opposing increase in their pH of fusion (27). When
mapped onto the atomic structure of the neutral-pH form of
HA, these mutations cluster at the HA1-HA2 interface and
proximate to the fusion peptide at the N terminus of HA2 (27).
The possible role of the fusion peptide and surrounding struc-
tures in stabilizing and destabilizing the prefusion HA complex
was independently highlighted by directed mutagenesis in this
region and in studies of the pH-associated effects of cell-cul-
ture adaptation and amantadine resistance (11, 35, 52). It re-
mains uncertain, however, whether the determinant for pH-
induced activation of HA is distributed or localized to a
specific region.
Our current model of the GPC complex proposes a pH-
sensitive interaction between the ectodomains of SSP and G2.
This interaction is stable at neutral pHs and thereby maintains
the GPC complex in its prefusion state. The interaction is
destabilized upon protonation at low pH to initiate the con-
formational cascade leading to class I type membrane fusion.
We now demonstrate that amino acid determinants for inhibi-
tion by the SIGA compounds likewise reside in SSP and G2.
Together, our observations suggest that these novel fusion
inhibitors act by interfering with the ability of the SSP-G2
interface to sense acidic pH or, subsequently, to respond pro-
ductively. This provides a starting point in efforts to character-
ize the molecular basis for pH-induced activation in GPC. The
abundance of charged residues in the membrane-proximal
ectodomain of G2 raises the possibility that the pH-sensing
interface may comprise an ensemble of titratable interactions
with K33 in SSP, similar perhaps to that recently described in
the acid-sensing ion channel 1 (30). Although atomic-resolu-
tion structure of the prefusion GPC complex is far in the
distance, localization of an element of the pH sensor to SSP
may facilitate efforts to characterize the molecular determi-
nants for pH-induced activation and its inhibition by small-
molecule compounds.
The unique subunit organization of GPC clearly provides a
robust molecular pocket for binding small molecules that are
capable of stabilizing the complex against acidic pH. At least
three chemically distinct classes of inhibitors, independently
identified in different arenavirus species, appear to target a
common site at the SSP-G2 interface. As with the chemically
diverse nonnucleoside analog inhibitors of human immunodefi-
ciency virus type 1 reverse transcriptase, all of which bind a com-
mon hydrophobic pocket (12, 31, 44), it is possible that the bound
forms of the SIGA inhibitors share spatial and chemical charac-
teristics. It will surely be of interest to determine whether the
chemically distinct GPC-directed fusion inhibitors described by
Lee and colleagues (34) bind similarly. If identified, this pharma-
cophore core may provide scaffolding in the design of potent and
broadly active second-generation inhibitors. To date, both ST-294
and ST-193 have shown promise in small-animal efficacy studies
(3, 33). Our observation that inhibition by these compounds is
profoundly sensitive to pH suggests that coadministration with
drugs that reduce acidification in the endosome might further
enhance their therapeutic efficacy.
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